
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.26 | 10.3585657371 | 2.51 | 3.23 | 2.47 | 1782591 | 2.88380021 | CS |
4 | 0.87 | 45.7894736842 | 1.9 | 3.23 | 1.8 | 1242242 | 2.416954 | CS |
12 | 0.3 | 12.1457489879 | 2.47 | 3.23 | 1.61 | 1238449 | 2.30814598 | CS |
26 | -3.43 | -55.3225806452 | 6.2 | 6.3065 | 1.61 | 992490 | 2.83297722 | CS |
52 | -6.9 | -71.354705274 | 9.67 | 11.2 | 1.61 | 794848 | 4.63958658 | CS |
156 | 0.22 | 8.62745098039 | 2.55 | 13.68 | 1.53 | 448189 | 5.20480545 | CS |
260 | -12.06 | -81.3216453136 | 14.83 | 25.87 | 1.53 | 305536 | 5.77689077 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions